FDA Announces New Pradaxa Study Results – Jackson Allen & Williams, LLP Takes Pradaxa Cases

Share Article

An FDA study found that the risk of gastrointestinal (GI) bleeding is higher with the use of the drug Pradaxa than it is with the use of warfarin. Jackson Allen & Williams represents individuals who suffered health complications after taking Pradaxa.

Jackson Allen & Williams, LLP

The U.S. Food and Drug Administration (FDA) had just released the results of a new study that compared the risk levels of certain serious health complication in two blood thinner drugs—Pradaxa and warfarin. The FDA made the announcement in a Drug Safety Communication* that was posted on the federal agency’s website on May 13, 2014. According to the announcement, it was discovered that Pradaxa had a higher risk of causing major gastrointestinal (GI) bleeding than warfarin. For other serious health complications, it was found that Pradaxa had a lower or similar risk level than the other drug. Dallas, Texas law firm Jackson Allen & Williams, LLP is currently accepting Pradaxa cases, or cases in which the law firm seeks rightful compensation for patients who were harmed as a result of taking Pradaxa.

Pradaxa and warfarin are anticoagulants that are used to help patients who have non-valvular atrial fibrillation (AF) lower their risk of blood clots and stroke, according to the FDA’s website. (AF is a condition that causes an abnormal rhythm of the heart.) In its recent study on Pradaxa and warfarin, the FDA used information from more than 134,000 Medicare patients who were 65 years old or older and who were using the drugs for the drugs for the first time. The study results showed that of the two blood thinners, Pradaxa had a higher risk of major GI bleeding. Meanwhile, warfarin was associated with a higher risk of bleeding in the brain, clot-based strokes and death. The drugs had similar risk levels for myocardial infarction (MI), or heart attack.

In the drug safety communication, the FDA noted that this study used a more sophisticated analytical method than the methods that was used in previous review of Pradaxa and warfarin. It also used an older and larger patient population. This study was one of multiple reviews that were conducted after the FDA learned of a high number of reports of bleeding in patients who used Pradaxa.

Jackson Allen & Williams is investigating the claims of individuals who suffered from internal bleeding, hemorrhaging or other harmful side effects after taking Pradaxa. The firm’s Dallas dangerous drug lawyers are ready to provide aggressive legal representation for these types of victims, who deserve to be compensated for the harmful health effects they have endured. Jackson Allen & Williams is inviting victims of Pradaxa and their family members to come forward so the firm can help them take action against the party that is responsible for their hardship. The law firm is able to assist with injury claims, as well as with wrongful death claims. Free case evaluations are available for those who would like to learn about their options for filing Pradaxa claims or lawsuits. More information about Jackson Allen & Williams is available at http://www.thepharmalawyer.com.

*http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm397179.htm

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Brad Jackson
@JAW_LLP_Law
since: 09/2012
Follow >
Jackson Allen & Williams, LLP
since: 06/2011
Like >
Follow us on
Visit website